Starting Dose for Hormone Therapy in Menopausal Women
Start with the lowest effective dose of hormone therapy, which for systemic estrogen typically means oral estradiol 0.5 mg daily or transdermal estradiol 0.025-0.05 mg/day, with upward titration only if symptoms persist. 1
Systemic Hormone Therapy Dosing
The Endocrine Society guideline emphasizes that the overarching principle is to use the lowest effective dose with upward titration based on clinical response 1. Starting doses are generally lower than those used in the Women's Health Initiative trials.
Estrogen Starting Doses by Route:
Oral formulations:
- Oral estradiol: Start at 0.5-1 mg daily
- Conjugated equine estrogens (CEE): Start at 0.3-0.45 mg daily (lower than the WHI dose of 0.625 mg)
Transdermal formulations (preferred for many patients):
- Transdermal estradiol patches: Start at 0.025-0.05 mg/day
- Gels, sprays, emulsions: Equivalent low doses, easily titrated 1
When to Use Higher Starting Doses:
For younger women with surgical menopause or premature ovarian insufficiency (POI), clinicians often prescribe higher starting doses (e.g., transdermal estradiol 100 µg) because these women are accustomed to higher baseline endogenous estradiol levels, then slowly lower the dose as tolerated 1. When these women approach the age of natural menopause, reassessment and dose tapering is reasonable.
Route Selection Matters for Safety
Transdermal estradiol is preferable over oral estrogen for women with:
- VTE risk
- Hypertension
- Hypertriglyceridemia
- Obesity or metabolic syndrome
- Diabetes
- History of gallbladder disease
This is because transdermal administration avoids the first-pass hepatic metabolic effect that causes procoagulant effects and increases in SHBG, triglycerides, and inflammatory markers like C-reactive protein 1. A meta-analysis commissioned for the Endocrine Society guidelines supports lower VTE risk with transdermal preparations 1.
Progestogen Dosing (for Women with a Uterus)
A progestogen must be added to prevent endometrial hyperplasia and cancer in women with an intact uterus 1.
Regimen Selection:
Combined continuous regimen (preferred for most):
- Both estrogen and progestogen daily
- Micronized progesterone 100-200 mg nightly (preferred)
- Or synthetic progestogens at appropriate doses
Combined sequential regimen (for recently menopausal women prone to breakthrough bleeding):
- Estrogen for 20-25 days
- Progestogen for 12-15 days each month
- Preferred during the first 1-2 years of therapy 1
Vaginal Estrogen for Genitourinary Symptoms Only
If symptoms are exclusively vaginal (genitourinary syndrome of menopause), use low-dose vaginal estrogen instead of systemic therapy:
Low-dose vaginal estradiol tablet:
- 10 µg tablet: Daily for 2 weeks, then twice weekly maintenance 1
- This is the most evidence-based low-dose option
- Relieves symptoms by 8 weeks, effective for at least 52 weeks
Low-dose vaginal ring:
- Releases estradiol maintaining postmenopausal levels
- Changed every 3 months 1
Intermediate-dose options (if low-dose insufficient):
- 25 µg estradiol tablets
- CEE 0.3 mg cream daily or twice weekly 1
Monitoring and Titration
Do not routinely measure estradiol levels to monitor therapy, except when:
- Symptoms fail to improve with escalating doses
- Changing from oral to transdermal administration 1
Titrate upward if symptoms persist after 4-8 weeks at the starting dose, but always aim to maintain the lowest effective dose.
Critical Pitfalls to Avoid
Don't use custom-compounded hormones - Use FDA-approved preparations only, as compounded therapies lack regulatory oversight and safety data 1
Don't measure salivary hormone levels - No scientific evidence supports this practice due to high variability 1
Don't use systemic-dose vaginal estrogen (CEE 0.625-2.5 mg cream) without adding progestogen in women with a uterus - these cause systemic effects 1
Don't start with high doses - The WHI used higher doses than currently recommended; modern practice emphasizes starting low